Enteric Disease Testing Market will grow at 2.5% CAGR, to be valued at US$ 4,432.7 Mn by 2027
Enteric Disease Testing Market – Insights
Enteric infection is a type of intestinal disease characterized by symptoms such as mild gastroenteritis, systemic infections, and severe diarrhea.
Intestinal infections in enteric diseases can range from asymptomatic and mild to severe symptoms including abdominal cramps, vomiting, nausea, and anorexia. Severe cases and symptoms under some cases may even lead to death as well due to heavy loss of fluids and essential nutrients from the body.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1164
The global enteric disease testing market is estimated to account for US$ 3,732.7 Mn in terms of value by the end of 2020.
Enteric Disease Testing Market: Drivers
Increasing prevalence of enteric infections among children is a major factor boosting growth of the enteric disease testing market. For instance, according to the World Health Organization (WHO), 2017, infectious gastroenteritis accounts for one billion cases of diarrhea and over two million deaths, annually worldwide. Moreover, according to Bill and Melinda Gates Foundation, 2017, enteric and diarrheal diseases lead to death of around 500,000 children, under the age of five, annually and children who survive repeated infections by gut pathogens in the early years of their life may suffer from lifelong health problems.
Increasing R&D of new products is expected propel growth of the market over the forecast period. For instance, in July 2014, Trinity Biotech plc. received CE marking for its new Uni-Gold H. pylori Antigen point-of-care test. The Uni-Gold H. pylori Antigen is a 15 min rapid test that is used in diagnosis of Helicobacter pylori (H. pylori) infection and to monitor the effectiveness of the treatment.
Moreover, increasing prevalence of diarrhea, cholera, and other diarrheal diseases is also expected to contribute to growth of the market. For instance, according to WHO, in 2017, 1.7 billion cases of diarrhea that resulted in over 2 million deaths were recorded worldwide. Moreover, children aged five years are particularly at risk and accounted for 760,000 fatalities, annually. Major organizations such as the WHO and UNICEF are focused on prevention and control of enteric infection, which is also expected to propel growth of the enteric disease testing market. According to Child Health Epidemiology Research Group (CHERG), enteric pathogens such as Salmonella spp., Rotavirus, and V. cholera caused more mortality as compared to other enteric pathogen. Therefore, the WHO has set the highest priority for R&D of improved vaccines against these pathogens.
Browse press release: https://www.coherentmarketinsights.com/press-release/enteric-disease-testing-market-3391
Enteric diseases are a major cause of morbidity and mortality in emerging economies, owing to poor drainage and sanitation facilities. For instance, typhoid fever and paratyphoid fever are the main causes of bacterial blood infections in children in Southeast Asia; children in many parts of Sub-Saharan Africa also suffer from typhoid.
Enteric Disease Testing Market: Restraints
However, lack of proper medical research infrastructure in emerging countries such as India and China is a major factor hindering growth of the market.
Enteric Disease Testing Market: Competitive Landscape
Major players operating in market are focused on product launch and approval to expand their product portfolio. For instance, in August 2017, Meridian Bioscience expanded its ImmunoCard STAT! product line by addition of ImmunoCard STAT FLU A&B that detects the presence of influenza A & B in nasal and nasopharyngeal swabs.
Key players operating in the global enteric disease testing market include Biomerica, Inc., Bio-Rad Laboratories, Inc., Meridian Bioscience Inc., BioConnections, Alere Inc., Biomerieux SA, Trinity Biotech plc., Quest Diagnostics Incorporated, Cepheid Inc., and DiaSorin.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1164
- In October 2019, Mobidiag Ltd, a molecular diagnostics company received CE marking for its Novodiag Stool Parasites test. The new test is used for the detection of intestinal parasites directly from stool samples.
- In March 2019, ERADA Technology Alliance Ltd (ERADA) launched saliva-based diagnostic tool, Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART), for detection of parasites causing malaria.
- In December 2018, Becton, Dickinson, and Company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its BD Max enteric viral panel, a molecular diagnostic test for the detection and differentiation of pathogens that cause viral gastroenteritis.
- In July 2017, TECHLAB, Inc., received U.S. FDA approval for its Tri-Combo Parasite Screen test, an all-in-one test for Giardia, Cryptosporidium, and Entamoeba Histolytica. The test is indicated for diagnosis of GI infection when giardiasis, cryptosporidiosis and amebiasis is suspected.
- In May 2015, DiaSorin launched LIAISON Campylobacter test for the global market excluding the U.S. The test reduces the time of obtaining results as well as with this patients can immediately know whether they are infected by the bacteria.
Enteric Disease Testing Market Taxonomy:
By Testing Type:
- Immunoassay Testing
- Conventional Testing
- Molecular Diagnostic Testing
By Disease Indication:
- Bacterial Enteric Disease
- Difficile Infection
- Coli Infection
- Pylori Infection
- Viral Enteric Disease
- Rotavirus Infection
- Norovirus Infection
- Parasitic Enteric Disease
By End User:
- Diagnostic Laboratories
- Research laboratories
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire